JANUS HENDERSON GROUP PLC - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
JANUS HENDERSON GROUP PLC ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$66,854,881
-17.0%
982,144
-0.4%
0.04%
-12.0%
Q2 2023$80,528,587
+9.7%
986,504
-0.3%
0.05%
+4.2%
Q1 2023$73,411,019
-10.2%
989,504
+0.3%
0.05%
-17.2%
Q4 2022$81,747,671
+15.4%
986,342
+97.9%
0.06%
+9.4%
Q3 2022$70,833,763
-18.0%
498,326
+99.9%
0.05%
-11.7%
Q2 2022$86,422,000
-27.1%
249,311
-8.9%
0.06%
+5.3%
Q1 2022$118,568,000
-33.8%
273,805
-20.9%
0.06%
-24.0%
Q4 2021$179,121,000
+8.4%
346,233
+1.5%
0.08%
+4.2%
Q3 2021$165,293,000
-9.5%
341,114
-15.9%
0.07%
-7.7%
Q2 2021$182,606,000
-8.7%
405,557
-22.6%
0.08%
-14.3%
Q1 2021$200,024,000
+7.7%
523,718
-10.4%
0.09%
+5.8%
Q4 2020$185,667,000
+1.2%
584,685
-21.1%
0.09%
-10.4%
Q3 2020$183,524,000
-17.5%
740,821
-12.1%
0.10%
-23.2%
Q2 2020$222,437,000
+38.0%
842,337
-0.9%
0.12%
+12.6%
Q1 2020$161,181,000
-39.7%
850,020
-30.2%
0.11%
-19.0%
Q4 2019$267,254,000
+3.2%
1,217,495
-8.0%
0.14%
-2.1%
Q3 2019$258,950,000
-10.1%
1,323,402
-4.2%
0.14%
-10.3%
Q2 2019$287,913,000
+3.2%
1,380,936
-1.7%
0.16%
+0.6%
Q1 2019$278,955,000
+33.8%
1,404,951
-2.5%
0.16%
+16.5%
Q4 2018$208,480,000
-26.7%
1,440,576
+3.4%
0.13%
-12.5%
Q3 2018$284,302,000
+37.9%
1,392,887
-0.0%
0.15%
+29.9%
Q2 2018$206,098,000
+3.6%
1,393,027
+5.8%
0.12%0.0%
Q1 2018$198,842,000
+24.2%
1,316,489
+6.6%
0.12%
+18.2%
Q4 2017$160,044,000
+17.8%
1,235,379
+9.9%
0.10%
+13.8%
Q3 2017$135,844,000
-2.7%
1,123,700
-5.4%
0.09%
-8.4%
Q2 2017$139,603,000
+402.0%
1,188,108
+334.3%
0.10%
-51.3%
Q1 2017$27,807,000
-5.7%
273,554
-4.6%
0.20%
-10.1%
Q4 2016$29,490,000
-6.2%
286,786
-0.1%
0.22%
-6.5%
Q3 2016$31,438,000
-3.5%
287,104
-0.6%
0.23%
-14.4%
Q2 2016$32,570,000
+82.9%
288,812
+53.3%
0.27%
+88.2%
Q1 2016$17,806,000
+2.0%
188,382
-2.8%
0.14%
+2.9%
Q4 2015$17,449,000
-1.3%
193,878
+1.4%
0.14%
-10.3%
Q3 2015$17,684,000
-4.0%
191,259
+2.3%
0.16%
+7.6%
Q2 2015$18,413,000
-22.3%
186,993
+4.5%
0.14%
-20.8%
Q1 2015$23,684,000
+37.3%
178,953
-4.2%
0.18%
+47.6%
Q4 2014$17,255,000186,7280.12%
Other shareholders
BIO-TECHNE CORP shareholders Q1 2022
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders